Aprogen Biologics Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported negative sales was KRW 0.00034 million compared to KRW 0.00038 million a year ago. Net income was KRW 4,473.33 million compared to KRW 2,685.71 million a year ago. Basic earnings per share from continuing operations was KRW 11 compared to KRW 7 a year ago. Diluted earnings per share from continuing operations was KRW 11 compared to KRW 7 a year ago. Basic earnings per share was KRW 11 compared to KRW 7 a year ago.
For the nine months, sales was KRW 37.99 million compared to KRW 733.48 million a year ago. Net income was KRW 10,391.56 million compared to KRW 6,322.39 million a year ago. Basic earnings per share from continuing operations was KRW 26 compared to KRW 16 a year ago. Diluted earnings per share from continuing operations was KRW 26 compared to KRW 16 a year ago. Basic earnings per share was KRW 26 compared to KRW 16 a year ago.